Hemostemix Closed $320,125 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit sold consisted of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per...
2023-10-03 10:55 AM EDT
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall consist of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common...
2023-09-27 5:10 PM EDT
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications of Implantable Biosensors Supporting Brain Computer Interfaces is co-authored by Dr. Chris McNorgan, Dr. Fraser C. Henderson, Sr., Dr. Ina Sarel, Dr. Ken Webb and Dr. Jeong Soo Lee. Within the last two...
2023-09-12 9:15 AM EDT
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in Montreal. "We are moving production of ACP-01 to Quebec, as have negotitated terms for a possible shared site where we can co-locate our staff to produce a treatment for clinical trials at 1/10th the cost of contract manufacturers," stated...
2023-08-29 1:58 PM EDT
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the International Center for Dispute Resolution (ICDR), International Abritration Tribunal, in the Matter of Arbitration between Elmar Burchardt vs Hemostemix Inc. The award stipulates Dr. Burchardt is to pay Hemostemix Inc. CAD $315,684 of its costs. Certified, for the purposes of Article I of the New...
2023-08-14 9:06 AM EDT
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal. The study, Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Treatment of Cardiomyopathy, was co-authored by Jane R. Schubart PhD, Amirhossein Zare MD, Roberto M. Fernandez-de-Castro MD, MSc, Hector Rosario...
2023-08-08 11:45 AM EDT
Hemostemix Closes $403,539 of the Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - June 28, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96. In connection with the Closing, the Corporation will pay finder fees ("Finder Fees") to one or more advisors, dealers or finders ("Finders") for their assistance in the Private Placement including: (a) a Finder's fee payable in cash not to exceed...
2023-06-28 8:56 AM EDT
Hemostemix's Private Placement Use of Proceeds
Calgary, Alberta--(Newsfile Corp. - June 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract in the form of a production facility cotenancy agreement negotiated by the Issuer, pay current filing, regulatory, and finder fees in connection with the offering, and for general working capital purposes. As stated in the previous news...
2023-06-21 4:52 PM EDT
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 10 Million Units priced at $0.12 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one half of one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.25 per Common Share for a...
2023-06-01 8:58 PM EDT
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
Calgary, Alberta--(Newsfile Corp. - May 2, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a company who is pursuing neural electrode-based brain intervention. Dr. McNorgan's research - the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention - is directly relatable...
2023-05-02 10:35 AM EDT
Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
Calgary, Alberta--(Newsfile Corp. - April 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business Development. The EVP Business Development will be responsible for building and leading a team focused on the following: The sale of Tranch 1 - 500 ACP treatment convertible debentures at USD $35,000 each, to...
2023-04-03 9:21 AM EDT
Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia "CLI" and peripheral arterial disease "PAD" patients, globally. The purpose of the revisions are to engage with CLI and PAD patients, to provide them with ACP-01 as limb saving treatment, and to provide them...
2023-03-29 12:45 PM EDT
Hemostemix Closes $762,400 of The Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering"). The Offering consisted of the issuance of an aggregate of 3,812,000 Units at a price of $0.20 per Unit. Each Unit consists of one common share in the capital of the...
2023-03-21 1:55 PM EDT
Hemostemix Unit Offering Repriced
Calgary, Alberta--(Newsfile Corp. - March 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its offering of 14 Million Common Share Units to $0.20 each. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per Common Share for a period of 24 months from the closing of the...
2023-03-08 3:02 PM EST
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
Calgary, Alberta--(Newsfile Corp. - March 7, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unsecured convertible debentures ("CD") at USD $35,000 each. The CD can be converted into one of 500 ACP-01 therapeutic production slots ("TPS"), subject to patients' compassionate exemption from regulatory approval, or is convertible into Common Shares of Hemostemix as described below. Tranche 1 of the...
2023-03-07 9:00 AM EST
Hemostemix Announces Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - February 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 14 Million Units priced at $0.24 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per Common Share for a period of...
2023-02-01 8:31 PM EST
The Force Family Office Engaged by Hemostemix
Calgary, Alberta--(Newsfile Corp. - January 31, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is plugged into the largest network of family offices in the United States via its agreement with the Force Family Office. In 2022, The Force Family Office hosted more than 150 events, connecting family offices with private and public companies for co-investment. Founded in 2020 by Steven Saltzstein with a singular focus to...
2023-01-31 9:26 AM EST
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
Calgary, Alberta--(Newsfile Corp. - January 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its Trademark, Your Fountain of Youth, was granted protection in Switzerland by its Trademark Office. Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., has received a Statement of Grant of Protection from the Swiss Trademark Office, and notice of the grant from the World Intellectual Property Organization....
2023-01-30 3:50 PM EST
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your Fountain of Youth explains the benefit of leveraging your synergetic cell population as ACP-01 and it explains Hemostemix' business model," stated Thomas...
2023-01-26 3:27 PM EST
Hemostemix Wins Arbitration Decision
Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that it was entered into in violation of Dr. Burchardt's duties as a director under sections 120 and 122 of the Business Corporations Act (Alberta), and determined that he...
2023-01-24 9:00 AM EST